DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer Clinical Trial

Official title:

A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303c Versus Trastuzumab Emtansine in Patients With HER2-positive Advanced Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06313086
• Other study ID #: SYSA1501-009
• Secondary ID: CTR20240245
• Status: Recruiting
• Phase: Phase 3
• Start date: March 13, 2024
• Est. completion date: February 2028

Study information

• Verified date: December 2023
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: Clinical Trials Information Group officer
• Phone: 86-0311-69085587
• Email: ctr-contact[@]cspc.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer

Description:

This is a multi-centre, randomized, open-label, controlled phase Ш clinical study to evaluate the efficacy and safety of DP303c injection versus trastuzumab emtansine in in patients with HER2-positive advanced breast cancer. Patients will be treated with DP303c injection at 3.0 mg/kg or trastuzumab emtansine at 3.6 mg/kg every 3 weeks. Patients will continue to receive treatment until disease progression, intolerable toxicity, withdrawal of informed consent, death, or any other reasons for treatment discontinuation, whichever occurs first.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 442
• Est. completion date: February 2028
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1.Voluntarily agree to participate in the study and sign the informed consent;

• 2.Age=18 years old;

• 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology;

• 4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive);

• 5.Previously received regimens containing trastuzumab and taxanes at the advanced stage of disease.

• 6.The Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;

• 7.Patients with adequate organ functions;

• 8.Life expectancy = 3 months;

• 9.Female and male patients of childbearing age must agree to take adequate contraceptive measures during the entire study period.

Exclusion Criteria:

• 1. Patients who have previously received tubulin inhibitor-loaded HER2 ADC therapy

• 2. History of any other malignant tumors within three years

• 3. With uncontrollable serous effusion within 14 days before randomization, which required frequent drainage or medical intervention.

• 4. Known contraindication to the study drugs;

• 5. Has not recovered from adverse reactions caused by previous anti-tumor treatments to = Grade 1 or baseline (refer to NCI CTCAE 5.0);

• 6. NCI-CTCAE 5.0 =Grade 2 peripheral nephropathy occurred during previous systemic anti-tumor treatment;

• 7. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization .

• 8. Major organ surgery (excluding needle biopsy) within 28 days before randomization;

• 9. Untreated (including baseline findings) or unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis.

• 10.The cumulative amount of previous exposure to anthracyclines has reached the dosage;

• 11.History of LVEF < 40%, symptomatic congestive heart failure (CHF),

• 12.Serious or uncontrolled cardiovascular disease;

• 13.History of (non-infectious) interstitial lung disease/pneumonitis requiring steroid hormone therapy;

• 14.Patients who currently have ocular diseases that require medication or surgical intervention; or unwilling to stop wearing contact lenses during the study.

• 15.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization;

• 16.There are other circumstances that may interfere with the subject's participation in the study procedures or do not meet the subject's maximum benefit from participating in the study or affect the study results.

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Breast Cancer

Intervention

Drug:
• DP303c
intravenous injection
• trastuzumab emtansine
intravenous injection

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS) by BIRC	PFS is evaluated by a Blinded Independent Review Committee (BIRC) according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.	Up to approximately 4 years
Secondary	Progression-free survival (PFS) by investigator	PFS is evaluated by investigator according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.	Up to approximately 4 years
Secondary	Overall Survival (OS)	Overall Survival	Up to approximately 4 years
Secondary	Objective response rate (ORR)	ORR is evaluated by investigator and BIRC according to the Response Evaluation Criteria for Solid Tumors (RECIST) V1.1.	Up to approximately 4 years
Secondary	Duration of response (DoR)	Duration of Response	Up to approximately 4 years
Secondary	Incidence and severity of adverse events (AEs)	Incidence and severity of adverse events	Up to approximately 4 years